Cargando…

Pathogenesis of prostate cancer and hormone refractory prostate cancer

Prostate cancer is the second most common malignancy in males and the leading cause of cancer death. Prostate cancer is initially androgen dependent and relies upon the androgen receptor (AR) to mediate the effects of androgens. The AR is also the target for therapy using antiandrogens and LHRH anal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Girling, J. S., Whitaker, H. C., Mills, I. G., Neal, D. E.
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2007
Materias:	Symposium
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721494/ https://www.ncbi.nlm.nih.gov/pubmed/19675761 http://dx.doi.org/10.4103/0970-1591.30265

Ejemplares similares

Update in palliative management of hormone refractory cancer of prostate
por: Singh, Pratipal, et al.
Publicado: (2007)

Chemotherapy for hormone-resistant prostate cancer: Where are we today?
por: Buchler, Tomas, et al.
Publicado: (2007)

Treatment algorithm in hormone-resistant prostate cancer: Practical guidelines
por: Khochikar, Makarand V.
Publicado: (2007)

BPH and prostate cancer risk
por: Miah, Saiful, et al.
Publicado: (2014)

Use of bisphosphonates in prostate cancer: Current status
por: Nayyar, Rishi, et al.
Publicado: (2007)

New therapeutic targets in the treatment of prostate cancer
por: Vijjan, Vivek, et al.
Publicado: (2007)

Hormonal manipulation of lower urinary tract symptoms secondary to benign prostatic obstruction
por: Raja, Adita, et al.
Publicado: (2014)

Role of robot-assisted radical prostatectomy in the management of high-risk prostate cancer
por: Sood, Akshay, et al.
Publicado: (2014)

Management of large prostatic adenoma: Lasers versus bipolar transurethral resection of prostate
por: Gupta, Narmada P, et al.
Publicado: (2013)

Leptomeningeal Metastases in Hormone Refractory Prostate Cancer
por: Ng, Jessica Y, et al.
Publicado: (2018)

bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer.
por: Apakama, I., et al.
Publicado: (1996)

Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
por: Armstrong, Andrew J, et al.
Publicado: (2007)

Evolution and success of holmium laser enucleation of the prostate
por: Krambeck, Amy E.
Publicado: (2010)

Tuberculosis of the prostate and urethra: A review
por: Gupta, Nitin, et al.
Publicado: (2008)

Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction
por: Patel, Nishant D., et al.
Publicado: (2014)

Multimodality treatment in hormone-refractory prostate cancer patients with bone metastases
por: Lam, Marnix G. E. H., et al.
Publicado: (2008)

The changing landscape of hormonal therapy in castration-resistant prostate cancer
por: Dongre, Amol, et al.
Publicado: (2012)

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
por: Sinibaldi, Victoria J
Publicado: (2007)

Surgical therapy for benign prostatic hypertrophy/bladder outflow obstruction
por: Thiruchelvam, Nikesh
Publicado: (2014)

Hormone refractory prostate cancer: Current understanding and future perspectives
por: Khochikar, Makarand
Publicado: (2007)

Phosphorylation of the Androgen Receptor by PIM1 in Hormone Refractory Prostate Cancer
por: Ha, Susan, et al.
Publicado: (2012)

TITAN trial; shifting focus from hormone-refractory to hormone-sensitive prostate cancer
por: Kumar, Gautam
Publicado: (2020)

Combination Effects of Docetaxel and Doxorubicin in Hormone-Refractory Prostate Cancer Cells
por: Tsakalozou, Eleftheria, et al.
Publicado: (2012)

The surgical management of the refractory overactive bladder
por: Vasdev, Nikhil, et al.
Publicado: (2010)

Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer
por: Edwards, J, et al.
Publicado: (2003)

Robotic surgery beyond the prostate
por: Aron, Monish
Publicado: (2014)

Multifunctionality of prostatic acid phosphatase in prostate cancer pathogenesis
por: Alpert, Evgenia, et al.
Publicado: (2021)

Prostate cancer detection: Fusion of cytological and textural features
por: Nguyen, Kien, et al.
Publicado: (2012)

Non-Hormonal treatment of BPH/BOO
por: Osman, Nadir I., et al.
Publicado: (2014)

Brief assessment of priority symptoms in hormone refractory prostate cancer: The FACT Advanced Prostate Symptom Index (FAPSI)
por: Yount, Susan, et al.
Publicado: (2003)

Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer
por: Tam, L, et al.
Publicado: (2007)

Abiraterone acetate, an inhibitor of adrenal androgen synthesis in “hormone refractory prostate cancer”
por: Goel, Arun Kumar, et al.
Publicado: (2011)

Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer
por: Calcagno, Fabien, et al.
Publicado: (2012)

EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment
por: Guérin, Olivier, et al.
Publicado: (2010)

Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer
por: Hu, Meichun, et al.
Publicado: (2015)

Hormones in pregnancy
por: Kumar, Pratap, et al.
Publicado: (2012)

Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients
por: McCall, P, et al.
Publicado: (2008)

Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer
por: Birtle, A J, et al.
Publicado: (2004)

Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine.
por: de Souza, P. L., et al.
Publicado: (1997)

A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer
por: Collins, R, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_0t1j8g441oq0gqsmplka6lng8c